文献
J-GLOBAL ID:201802272784851135
整理番号:18A0392779
ヒトiPS細胞由来心筋細胞を用いた薬物誘発torsadogenicリスク評価のための新しいパラダイム【Powered by NICT】
A new paradigm for drug-induced torsadogenic risk assessment using human iPS cell-derived cardiomyocytes
著者 (46件):
Ando Hiroyuki
( http://jicsa.org/.)
,
Ando Hiroyuki
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Ando Hiroyuki
(Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni-cho, Sakai-shi, Fukui 913-8538, Japan)
,
Yoshinaga Takashi
( http://jicsa.org/.)
,
Yoshinaga Takashi
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Yoshinaga Takashi
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Yamamoto Wataru
( http://jicsa.org/.)
,
Yamamoto Wataru
(Pharmaceutical Development Research Laboratories, Toxicology Research Department, Teijin Pharma Limited, 4-3-2 Asahigaoka, Hino-shi, Tokyo 191-8512, Japan)
,
Asakura Keiichi
( http://jicsa.org/.)
,
Asakura Keiichi
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Asakura Keiichi
(Discovery Research Labs., Nippon Shinyaku Co., Ltd., 14 Nishinosho-monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan)
,
Uda Takaaki
( http://jicsa.org/.)
,
Uda Takaaki
(Safety Research Laboratories, Ono Pharmaceutical Co., Ltd., 50-10 Yamagishi, Mikuni-cho, Sakai-shi, Fukui 913-8538, Japan)
,
Taniguchi Tomohiko
( http://jicsa.org/.)
,
Taniguchi Tomohiko
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Ojima Atsuko
( http://jicsa.org/.)
,
Ojima Atsuko
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Shinkyo Raku
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Kikuchi Kiyomi
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Osada Tomoharu
( http://jicsa.org/.)
,
Osada Tomoharu
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Osada Tomoharu
(Drug Development Service Segment, LSI Medience Corporation, 13-4 Uchikanda 1-chome, Chiyoda-ku, Tokyo 101-8517, Japan)
,
Hayashi Seiji
( http://jicsa.org/.)
,
Hayashi Seiji
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Hayashi Seiji
(Discovery Research Labs., Nippon Shinyaku Co., Ltd., 14 Nishinosho-monguchi-cho, Kisshoin, Minami-ku, Kyoto 601-8550, Japan)
,
Kasai Chieko
( http://jicsa.org/.)
,
Kasai Chieko
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Kasai Chieko
(Drug Safety Research Laboratories, Astellas Pharma Inc., 21, Miyukigaoka, Tsukuba-shi, Ibaraki 305-8585, Japan)
,
Miyamoto Norimasa
( http://jicsa.org/.)
,
Miyamoto Norimasa
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Tashibu Hiroyuki
( http://jicsa.org/.)
,
Tashibu Hiroyuki
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Tashibu Hiroyuki
(Research Administration Department, Ina Research Inc., 2148-188 Nishiminowa, Ina-shi, Nagano 399-4501, Japan)
,
Yamazaki Daiju
( http://jicsa.org/.)
,
Yamazaki Daiju
(Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan)
,
Sugiyama Atsushi
( http://jicsa.org/.)
,
Sugiyama Atsushi
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Sugiyama Atsushi
(Department of Pharmacology, Faculty of Medicine, Toho University, 5-21-16 Omori-nishi, Ota-ku, Tokyo 143-8540, Japan)
,
Kanda Yasunari
( http://jicsa.org/.)
,
Kanda Yasunari
(Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan)
,
Sawada Kohei
( http://jicsa.org/.)
,
Sawada Kohei
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Sawada Kohei
(Biopharmaceutical Assessments Core Function Unit, Medicine Development Center, Eisai Co., Ltd., 5-1-3 Tokodai, Tsukuba, Ibaraki 300-2635, Japan)
,
Sekino Yuko
( http://jicsa.org/.)
,
Sekino Yuko
(Japanese Safety Pharmacology Society (JSPS), 3-39-22 Showa-machi, Maebashi, Gunma 371-8511, Japan http://www.j-sps.org/.)
,
Sekino Yuko
(Division of Pharmacology, National Institute of Health Sciences (NIHS), 1-18-1 Kamiyoga, Setagaya-ku, Tokyo 158-8501, Japan)
資料名:
Journal of Pharmacological and Toxicological Methods
(Journal of Pharmacological and Toxicological Methods)
巻:
84
ページ:
111-127
発行年:
2017年
JST資料番号:
A0132B
ISSN:
1056-8719
CODEN:
JPTMEZ
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
オランダ (NLD)
言語:
英語 (EN)